Exploring depression in people with schizophrenia spectrum disorders: A cross-sectional analysis of the clinical relationship with Positive and Negative Syndrome Scale dimensions.

OBJECTIVE: Evidence on the relationship of depression with clinical dimensions of schizophrenia remains limited. This cross-sectional study aimed at exploring the association of depression with the Positive and Negative Syndrome Scale (PANSS) dimensions in people with schizophrenia spectrum disorders (SSD). METHODS: Trained assessors administered PANSS to measure core symptoms of schizophrenia and the Calgary Depression Scale for Schizophrenia (CDSS) to measure depressive features. Multiple logistic regression analyses were carried out to analyse the association of depression with PANSS overall score and related dimensions. RESULTS: We included 231 inpatients with SSD (mean age:42.4±12.9 years; males: 58.9%; mean PANSS overall score:82.5±20.1; drug-free or naïve: 39.3%), including 78 (33.8%) with clinically significant depressive symptoms. Depression was associated with higher overall (regression coefficient [coeff.], standard error [SE]: 0.029, 0.008; p<0.001) and General Psychopathology (coeff., SE: 0.118, 0.023; p<0.001) PANSS scores. We found an inverse relationship between depression and positive symptoms (coeff., SE: -0.088, 0.028; p=0.002). No association between depressive and negative symptoms was estimated. CONCLUSIONS: Despite some limitations, our study shows that people affected by SSD with depressive features are likely to show more overall and general psychopathology symptoms, though lower positive symptoms. Additional studies are needed to explore the generalizability of our findings.

Increased Risk of Metabolic Syndrome in Antidepressants Users: A Mini Review.

Mounting evidence has shown that the risk of metabolic syndrome (MetS) is substantially overlapping in the diagnostic subgroups of psychiatric disorders. While it is widely acknowledged that patients receiving antipsychotic medications are at higher risk of MetS than antipsychotic-naive ones, the association between antidepressants and MetS is still debated. The goal of our mini review was to analyse the relationship among depressive symptoms, antidepressant use and the occurrence of MetS. Adhering to PRISMA guidelines, we searched MEDLINE, reference lists and journals, using the following search string: ((("Mental Disorders"[Mesh]) AND "Metabolic Syndrome"[Mesh]) AND "Antidepressive Agents"[Mesh]), and retrieved 36 records. Two reviewers independently assessed records and the mini review eventually included the data extracted from 8 studies. The Newcastle-Ottawa Scale was used to assess the quality of the selected studies. Overall, the results of the mini review seem to support the association among depressive symptoms, antidepressants therapy and MetS. Except for H1-R high-affinity ones, the relationship between antidepressants and MetS still needs to be clarified. Considering the widespread prescription of antidepressants, both on behalf of psychiatrists and primary care physicians, further research on this topic is recommended.